Transient ischemic attack (TIA) is often a precursor to major ischemic stroke, and appropriate ... are included in the new guidelines: initial management; evaluation; medical treatment; surgical ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

In patients with acute ischemic stroke, guidelines recommend withholding antihypertensive treatment until systolic blood pressure exceeds 220 mm Hg or diastolic BP exceeds 120 mm Hg (Stroke 2007 ...

Children with sickle cell disease, a chronic hemolytic anemia, present with a wide variety of neurological syndromes, including ischemic and hemorrhagic stroke, transient ischemic attacks ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

In 2015, several randomized trials showed the benefit of endovascular therapy compared with medical management ... with acute ischemic stroke as well as patient selection criteria," says ...

"Given the widespread use of these products and the severity of arterial thrombotic events, the findings have important public health implications," the authors write. HealthDay News ...

There is a dose-response relationship between maternal body mass index (BMI) and perinatal ischemic stroke (PIS) risk ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...